Price Alert

Intra-Cellular Therapies ... (ITCI)

NASDAQ: ITCI · Real-Time Price · USD

131.87

0.00 (0.00%)

At close: Apr 01, 2025, 3:59 PM

Intra-Cellular Therapies Statistics

Share Statistics

Intra-Cellular Therapies has 106.52M shares outstanding. The number of shares has increased by 0.81% in one year.

Shares Outstanding	106.52M
Shares Change (YoY)	0.81%
Shares Change (QoQ)	0%
Owned by Institutions (%)	92.31%
Shares Floating	104.82M
Failed to Deliver (FTD) Shares	41
FTD / Avg. Volume	n/a

Short Selling Information

The latest short interest is 2.59M, so 0% of the outstanding shares have been sold short.

Short Interest	2.59M
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	1.84

Valuation Ratios

The PE ratio is -115.34 and the forward PE ratio is 30.6. Intra-Cellular Therapies's PEG ratio is 2.28.

PE Ratio	-115.34
Forward PE	30.6
PS Ratio	12.65
Forward PS	9.8
PB Ratio	7.5
P/FCF Ratio	-117.19
PEG Ratio	2.28

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Intra-Cellular Therapies.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 6.36, with a Debt / Equity ratio of 0.01.

Current Ratio	6.36
Quick Ratio	6.23
Debt / Equity	0.01
Debt / EBITDA	-0.15
Debt / FCF	-0.23
Interest Coverage	0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$791.69K
Profits Per Employee	$-86.83K
Employee Count	860
Asset Turnover	0.5
Inventory Turnover	2.17

Taxes

Income Tax	473K
Effective Tax Rate	-0.64%

Stock Price Statistics

The stock price has increased by 76.06% in the last 52 weeks. The beta is 0.46, so Intra-Cellular Therapies's price volatility has been higher than the market average.

Beta	0.46
52-Week Price Change	76.06%
50-Day Moving Average	129.42
200-Day Moving Average	92.67
Relative Strength Index (RSI)	84.54
Average Volume (20 Days)	3,621,742

Income Statement

In the last 12 months, Intra-Cellular Therapies had revenue of 680.85M and earned -74.68M in profits. Earnings per share was -0.72.

Revenue	680.85M
Gross Profit	623.89M
Operating Income	-116.72M
Net Income	-74.68M
EBITDA	-116.72M
EBIT	-116.72M
Earnings Per Share (EPS)	-0.72

Full Income Statement

Balance Sheet

The company has 306.95M in cash and 16.98M in debt, giving a net cash position of 289.97M.

Cash & Cash Equivalents	306.95M
Total Debt	16.98M
Net Cash	289.97M
Retained Earnings	-1.69B
Total Assets	1.37B
Working Capital	1.1B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -73.18M and capital expenditures -322K, giving a free cash flow of -73.5M.

Operating Cash Flow	-73.18M
Capital Expenditures	-322K
Free Cash Flow	-73.5M
FCF Per Share	-0.71

Full Cash Flow Statement

Margins

Gross margin is 91.63%, with operating and profit margins of -17.14% and -10.97%.

Gross Margin	91.63%
Operating Margin	-17.14%
Pretax Margin	-10.9%
Profit Margin	-10.97%
EBITDA Margin	-17.14%
EBIT Margin	-17.14%
FCF Margin	-10.8%

Dividends & Yields

ITCI does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for ITCI is $132, which is 0.1% higher than the current price. The consensus rating is "Hold".

Price Target	$132
Price Target Difference	0.1%
Analyst Consensus	Hold
Analyst Count	8

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	38.03
Piotroski F-Score	2